Clinical Trial Update: Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC

View source ↗

Summary

A clinical trial is evaluating nintedanib for preventing radiation pneumonitis in patients with unresectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Radiation Pneumonitis

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Second Hospital of Shanxi Medical University | Conditions: NSCLC, Nintedanib | Status: RECRUITING